by Colfar | agosto 31, 2017 12:47 pm
Farmacovigilancia. NatalizumabSource URL: https://colfarsfe.org.ar/2017/08/31/natalizumab-tysabri-riesgo-potencial-de-anormalidades-hematologicas-en-recien-nacidos-de-madres-tratadas-durante-el-embarazo-con-tysabri-hc-anmat/
Copyright ©2024 Colegio de Farmacéuticos de Santa Fe 1 Circ. unless otherwise noted.